By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

European Commission (EC) 

Rue Joseph II
Jozef II straat 70
Brussels    B-1000  Belgium
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Medical Device






Company News
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Single Tablet Regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) For The Treatment Of HIV 6/23/2016 10:45:55 AM
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 6/2/2016 12:02:14 PM
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves TREVICTA (Paliperidone Palmitate A 3-Monthly Injection), For Maintenance Treatment Of Schizophrenia 5/31/2016 11:28:04 AM
AbbVie (ABBV) Release: European Commission (EC) Approves IMBRUVICA (Ibrutinib) For First-Line Treatment Of Patients With Chronic Lymphocytic Leukemia 5/31/2016 6:24:02 AM
European Commission (EC) Approves IDELVION --CSL Behring's Novel Hemophilia B Treatment With Up To 14-Day Dosing Intervals 5/11/2016 11:17:28 AM
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma 5/11/2016 10:53:05 AM
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Fixed-Dose Combination Descovy (Emtricitabine, Tenofovir Alafenamide) For Treatment Of HIV 4/25/2016 10:08:35 AM
European Commission (EC) Approves Expanded Use Of Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) To Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer 4/6/2016 11:05:08 AM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) For Previously Treated Advanced Renal Cell Carcinoma 4/6/2016 11:02:49 AM
Takeda (TKPYY) Release: European Commission (EC) Approves Label Variation For ADCETRIS (Brentuximab Vedotin) To Include Data On Retreatment Of Adult Patients With Relapsed Or Refractory Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma (sALCL) 1/22/2016 10:12:17 AM
12345678910...
//-->